title: G-CSF Dosing to Prevent Recurrent Clozapine-Induced Agranulocytosis.
authors.affiliation: From the Department of Psychiatry and Behavioral Sciences, and the Division of Hematology, Stanford University Medical Center, Stanford, Calif.
authors.forename: G Mark
authors.initials: GM
authors.lastname: Freeman
authors.affiliation: From the Department of Psychiatry and Behavioral Sciences, and the Division of Hematology, Stanford University Medical Center, Stanford, Calif.
authors.forename: Beth A
authors.initials: BA
authors.lastname: Martin
authors.affiliation: From the Department of Psychiatry and Behavioral Sciences, and the Division of Hematology, Stanford University Medical Center, Stanford, Calif.
authors.forename: Rona J
authors.initials: RJ
authors.lastname: Hu
mesh_terms: D000380:Agranulocytosis / Q000139:chemically induced* / Q000517:prevention & control; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003024:Clozapine / Q000009:adverse effects*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011618:Psychotic Disorders / Q000188:drug therapy; D012008:Recurrence; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D016179:Granulocyte Colony-Stimulating Factor; D003024:Clozapine